Rhythm Pharmaceuticals, Inc. Common Stock (RYTM) Stock Price

RYTMStock

$113.35+7.91%52W

Market Cap$7.80B

P/E—

PEG Ratio—

Div yield—

Beta2.00

RYTM Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-1.24%

Price vs S&P 500 (4W)0.10%

VGM Score51.75

Book Value / Share (Quarterly)$3.16

P/TBV (Annual)26.99x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)100.22%

Cash Flow / Share (Quarterly)$-1.54

Price vs S&P 500 (YTD)-7.85%

Gross Margin (TTM)70.90%

Net Profit Margin (TTM)-85.59%

EPS (TTM)$-3.05

10-Day Avg Trading Volume0.54M

EPS Excl Extra (TTM)$-3.05

EPS (Annual)$-3.02

ROI (Annual)-51.97%

Gross Margin (Annual)89.73%

Net Profit Margin (5Y Avg)-703.67%

Cash / Share (Quarterly)$4.81

Revenue Growth QoQ (YoY)46.91%

ROA (Last FY)-40.93%

Revenue Growth TTM (YoY)53.51%

EBITD / Share (TTM)$-2.96

ROE (5Y Avg)-86.59%

Operating Margin (TTM)-83.62%

Cash Flow / Share (Annual)$-1.74

P/B Ratio37.45x

P/B Ratio (Quarterly)35.02x

Net Income / Employee (Annual)$-474,700

EV / Revenue (TTM)34.08x

Net Interest Coverage (TTM)-36.06x

ROA (TTM)-44.00%

EPS Incl Extra (Annual)$-3.02

Current Ratio (Annual)4.41x

Quick Ratio (Quarterly)3.00x

3-Month Avg Trading Volume0.76M

52-Week Price Return7.91%

Revenue / Employee (TTM)$579,500

Tangible BV / Share (Quarterly)$3.09

P/S Ratio (Annual)42.88x

Asset Turnover (Annual)0.40x

52-Week High$122.20

Operating Margin (5Y Avg)-1339.99%

EPS Excl Extra (Annual)$-3.02

CapEx CAGR (5Y)35.32%

Tangible BV CAGR (5Y)12.11%

26-Week Price Return10.01%

Quick Ratio (Annual)4.01x

13-Week Price Return23.56%

Total Debt / Equity (Annual)0.40x

Current Ratio (Quarterly)3.45x

Enterprise Value$8.18B

Asset Turnover (TTM)0.51x

Book Value / Share Growth (5Y)1.29%

Revenue / Employee (Annual)$458,400

Inventory Turnover (Annual)0.88x

Pretax Margin (Annual)-103.31%

Cash / Share (Annual)$5.79

3-Month Return Std Dev42.17%

Gross Margin (5Y Avg)87.94%

Net Income / Employee (TTM)$-496,000

ROE (Last FY)-72.79%

Net Interest Coverage (Annual)-52.02x

EPS Basic Excl Extra (Annual)$-3.02

Receivables Turnover (TTM)7.21x

Total Debt / Equity (Quarterly)0.49x

EPS Incl Extra (TTM)$-3.05

Receivables Turnover (Annual)8.51x

ROI (TTM)-56.56%

P/S Ratio (TTM)33.92x

Pretax Margin (5Y Avg)-703.42%

Revenue / Share (Annual)$2.92

Tangible BV / Share (Annual)$3.94

Price vs S&P 500 (52W)-10.40%

Year-to-Date Return4.11%

5-Day Price Return-3.31%

EPS Normalized (Annual)$-3.02

ROA (5Y Avg)-46.27%

Net Profit Margin (Annual)-103.57%

Month-to-Date Return12.28%

Cash Flow / Share (TTM)$-3.23

EBITD / Share (Annual)$-2.93

Operating Margin (Annual)-101.19%

LT Debt / Equity (Annual)0.37x

ROI (5Y Avg)-58.33%

LT Debt / Equity (Quarterly)0.43x

EPS Basic Excl Extra (TTM)$-3.05

P/TBV (Quarterly)35.82x

P/B Ratio (Annual)26.45x

Inventory Turnover (TTM)2.83x

Pretax Margin (TTM)-85.14%

Book Value / Share (Annual)$4.02

Price vs S&P 500 (13W)20.77%

Beta2.00x

Revenue / Share (TTM)$3.50

ROE (TTM)-80.48%

52-Week Low$74.50

vGradeF

gGradeB

mGradeC

vgmGradeC

RYTM Earnings Surprise History

Q2 25-0.75est. -0.67

Q3 25-0.82est. -0.73

Q4 25-0.73est. -0.78

Q1 26-0.83est. -0.86

Q2 26-0.73est. -0.83

RYTM Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.27

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$67.01

About Rhythm Pharmaceuticals, Inc. Common Stock

Rhythm Pharmaceuticals is a biopharmaceutical company focused on developing precision medicines for rare neuroendocrine and metabolic disorders. The company commercializes IMCIVREE (setmelanotide), an approved MC4R agonist for treating hyperphagia and severe obesity caused by rare genetic deficiencies in the MC4R pathway. Its pipeline includes two next-generation MC4R agonists designed to avoid hyperpigmentation and candidate therapies for congenital hyperinsulinism.